moxifloxacin has been researched along with Pancreatic Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Saini, N; Sultana, S; Varshney, P; Yadav, J; Yadav, V | 1 |
Adam, U; Drewelow, B; Förster, S; Hopt, UT; Klar, E; Mundkowski, RG; Wacke, R | 1 |
1 trial(s) available for moxifloxacin and Pancreatic Neoplasms
Article | Year |
---|---|
Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Humans; Infusions, Intravenous; Male; Middle Aged; Moxifloxacin; Pancreas; Pancreatic Neoplasms; Pancreatitis, Acute Necrotizing; Prospective Studies; Quinolines | 2006 |
1 other study(ies) available for moxifloxacin and Pancreatic Neoplasms
Article | Year |
---|---|
Moxifloxacin and ciprofloxacin induces S-phase arrest and augments apoptotic effects of cisplatin in human pancreatic cancer cells via ERK activation.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Cisplatin; Drug Synergism; Fluoroquinolones; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Moxifloxacin; Pancreatic Neoplasms; S Phase | 2015 |